FIELD: medicine.
SUBSTANCE: invention refers to immunology. Disclosed is monoclonal antibody capable of specifically binding to human complement C3 molecule with exposed thioether link, and strain of mouse hybridoma RKKK(P)764D.
EFFECT: disclosed antibody blocks alternative complement activation path and can find further application in creation of antibodies suitable for clinical applications.
4 cl, 5 dwg, 1 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| HUMANIZED ANTIBODY TO CONFORMATIONAL C3 EPITOPE CONSTITUENT OF HUMAN COMPLEMENT, DNA SEQUENCE (VERSIONS), EXPRESSION VECTOR CONTAINING DNA SEQUENCE (VERSIONS), AND OVARIAN CELLS' STRAIN OF CHINESE HAMSTER CHO-HUMC34-PRODUCER OF THIS HUMANIZED ANTIBODY | 2016 |
|
RU2630647C1 |
| HUMANISED ANTIBODY TO THE CONFORMATIONAL EPITOPE OF THE HUMAN COMPLEMENT COMPONENT C3 | 2018 |
|
RU2687609C1 |
| METHOD FOR TREATING DISSEMINATED INTRAVASCULAR COAGULATION BY INHIBITING MASP-2 DEPENDENT COMPLEMENT ACTIVATION | 2010 |
|
RU2600876C2 |
| ANAPHYLATOXIN C5A ANTIBODIES TO HUMAN | 2019 |
|
RU2731516C1 |
| METHOD FOR DETERMINING COMPLEMENT-ACTIVATING FUNCTION OF SARS-CoV-2 ANTIBODIES FOR PREDICTING SEVERITY OF COVID-19 | 2023 |
|
RU2818351C1 |
| METHOD OF PREDICTING SEVERITY OF SYSTEMIC INFLAMMATORY RESPONSE IN HUMAN BODY IN DISEASES | 2022 |
|
RU2808416C1 |
| METHOD FOR DETERMINING THE FUNCTIONAL ACTIVITY OF THE HUMAN COMPLEMENT SYSTEM FOR PREDICTING THE SEVERITY OF THE COURSE OF A SYSTEMIC INFLAMMATORY REACTION | 2021 |
|
RU2756764C1 |
| ANTIBODIES AGAINST FACTOR D AND THEIR USE | 2018 |
|
RU2799044C2 |
| COMPOSITIONS AND METHODS OF INHIBITING MASP-1, MASP-2 AND/OR MASP-3 FOR TREATMENT OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA | 2013 |
|
RU2655299C2 |
| METHOD OF DETERMINING THE ACTIVITY OF THE CLASSICAL AND ALTERNATIVE PATHWAYS OF THE MOUSE COMPLEMENT SYSTEM | 2022 |
|
RU2800363C1 |
